Genetic variation in antigen presentation and cancer immunotherapy

Lavanya Sivapalan; Valsamo Anagnostou

doi:10.1016/j.immuni.2021.12.010

Genetic variation in antigen presentation and cancer immunotherapy

Lavanya Sivapalan, Valsamo Anagnostou

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

Original language	English (US)
Pages (from-to)	3-6
Number of pages	4
Journal	Immunity
Volume	55
Issue number	1
DOIs	https://doi.org/10.1016/j.immuni.2021.12.010
State	Published - Jan 11 2022

ASJC Scopus subject areas

Infectious Diseases
Immunology and Allergy
Immunology

Access to Document

10.1016/j.immuni.2021.12.010

Cite this

@article{e8a05da598d14b8ebd8897d487693cb6,

title = "Genetic variation in antigen presentation and cancer immunotherapy",

abstract = "Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.",

author = "Lavanya Sivapalan and Valsamo Anagnostou",

year = "2022",

month = jan,

day = "11",

doi = "10.1016/j.immuni.2021.12.010",

language = "English (US)",

volume = "55",

pages = "3--6",

journal = "Immunity",

issn = "1074-7613",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Genetic variation in antigen presentation and cancer immunotherapy

AU - Sivapalan, Lavanya

AU - Anagnostou, Valsamo

PY - 2022/1/11

Y1 - 2022/1/11

N2 - Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

AB - Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

UR - http://www.scopus.com/inward/record.url?scp=85123568041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123568041&partnerID=8YFLogxK

U2 - 10.1016/j.immuni.2021.12.010

DO - 10.1016/j.immuni.2021.12.010

M3 - Comment/debate

C2 - 35021056

AN - SCOPUS:85123568041

SN - 1074-7613

VL - 55

SP - 3

EP - 6

JO - Immunity

JF - Immunity

IS - 1

ER -

Genetic variation in antigen presentation and cancer immunotherapy

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this